537-24-6

Usage

Uses

Used in Pharmaceutical Research:
3,5-Dibromotyrosine is used as a subject of interest in pharmaceutical research for its potential antioxidant and anti-inflammatory properties, which may contribute to the development of new drugs for various diseases.
Used in Biomedical Research:
In biomedical research, 3,5-Dibromotyrosine is utilized to explore its potential role in the development of new therapeutic agents, particularly for the treatment of cancer and other diseases, due to its unique chemical structure and biological activities.
Used in Marine Biology Studies:
3,5-Dibromotyrosine is used as a bioactive compound in marine biology studies to understand its role in the defense mechanisms of marine organisms such as sponges and algae against predators and pathogens.
Used in Drug Development:
3,5-Dibromotyrosine is employed in drug development as a potential lead compound for the creation of new pharmaceuticals, leveraging its antioxidant and anti-inflammatory properties to target a range of health conditions.

Upstream product

• 60-18-4 L-tyrosine 
• 300-38-9 3,5-dibromo-L-tyrosine 
• 556-02-5 ?Tyr 

Downstream Products

• 556-02-5 ?Tyr 
• 765952-41-8 methyl 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 80527-48-6 2,2,3,3,4,4,4-Heptafluoro-butyric acid 2,6-dibromo-4-[2-(2,2,3,3,4,4,4-heptafluoro-butyrylamino)-2-methoxycarbonyl-ethyl]-phenyl ester 
• 61039-29-0 2-Amino-3-(3,5-dibromo-4-hydroxy-phenyl)-propionic acid methyl ester; hydrochloride 

Relevant academic research and scientific papers

Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists

Prostate cancer (PC) is the most diagnosed type of malignancy in men and the major frequently cause of cancer-related death worldwide. The androgen receptor (AR) has become a promising drug target for the treatment of PC. Here, we reported the design, optimization and evaluation of pyridine tetrahydroisoquinoline thiohydantoin derivatives with improved activity and safety as potent AR antagonists. The most promising compound 42f exhibited potent inhibitory activity on AR and strongly blocked AR nuclear translocation. Moreover, 42f displayed promising in vitro antitumor activity toward AR-dependent prostate cancer cell lines (LNCaP) and also demonstrated therapeutic effects in LNCaP xenograft tumor model in mice (TGI: 79%) with no apparent toxicity observed in vivo. More importantly, 42f showed negligible penetration of the brain-blood barrier (BBB) compared with enzalutamide. These results provide a foundation for the development of a new class of androgen receptor antagonists for potential therapeutics against PC with lower seizurogenic risk for patients.

Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents

Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145 cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising in vitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists.

Composition of matter having bioactive properties

Particles of coordinated complex comprising a basic, hydrous polymer and a capacitance adding compound, as well as methods for their production, are described. These complexes exhibit a high degree of bioactivity making them suitable for a broad range of applications through their incorporation into conventional vehicles benefiting from antimicrobial and similar properties.

Ianthesines A-D, four novel dibromotyrosine-derived metabolites from a marine sponge, Ianthella sp.

Novel dibromotyrosine-derived metabolites, ianthesines A, B, C, and D, were isolated from an Australian marine sponge of the genus Ianthella sp. Their structures were elucidated using chemical and spectroscopic techniques. Ianthesines A, B, and D were derived from two dibromotyrosines. Ianthesine C is a tetramer possessing eight bromine atoms and its molecular weight is 1606. Ianthesines B-D showed Na,K-ATPase inhibitory activity in the range of 50-440 μM, whereas ianthesine A is inactive. (C) 2000 Elsevier Science Ltd.